N4 Pharma granted Europe patent with China equivalent on its way
Specialist pharmaceutical company N4 Pharma announced on Friday that it has been granted a patent for its ‘Nuvec’ cancer treatment and vaccine delivery system by the European Patent Office (EPO), specifically around its composition, particulate materials, and methods for making the particulate materials.
The AIM-traded firm said the patent added to existing grants in Australia and Japan.
It also confirmed that it had been informed by the Chinese Patent Office (CPO) of its intention to grant a patent in China in relation to Nuvec.
Discussions with other key patent authorities in the United States, Canada and India were continuing, the board said, with updates to be provided in due course.
“We are delighted that the EPO has now formally granted the European patent which is now validated across Europe,” said chief executive officer Nigel Theobald.
“This achieves another key step in our intellectual property strategy, where we are also making excellent progress following the notice of allowance made recently by the CPO for the potentially huge market of China and the ongoing discussions in other key jurisdictions.
“We look forward to updating the market on these in due course.”
At 1022 BST, shares in N4 Pharma were up 7.3% at 8.53p.